M&G plc’s Barinthus Biotherapeutics BRNS Stock Holding History

M&G plc’s Portfolio BRNS Stock Details BRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.2M	Hold	5,197,349	–	–	0.03%	255
2026 Q1	$5.2M	Hold	5,197,349	–	–	0.03%	266
2025 Q4	$5.2M	Hold	5,197,349	–	–	0.03%	267
2025 Q3	$5.2M	Hold	5,197,349	–	–	0.03%	271
2025 Q2	$5.2M	Hold	5,197,349	–	–	0.03%	268
2025 Q1	$5.2M	Hold	5,197,349	–	–	0.02%	273
2024 Q4	$5.2M	Hold	5,197,349	–	–	0.03%	277
2024 Q3	$5.2M	Hold	5,197,349	–	–	0.02%	273
2024 Q2	$5.2M	Hold	5,197,349	–	–	0.02%	264
2024 Q1	$10.4M	Buy	+5,197,349	New	+$14.7M	0.04%	194

Other funds holding BRNS

GLR Partners Columbia, Maryland $215M AUM

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

M&G plc's BRNS Position: Q2 2026 in Review

M&G plc held its Barinthus Biotherapeutics (BRNS) position steady in Q2 2026 at 5,197,349 shares worth $5.2M. The position accounts for 0.03% of the portfolio, ranked #255.

M&G plc first reported a position in BRNS in Q1 2024 and has held it in 10 quarters since. The position peaked at $10.4M in Q1 2024. 3 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

M&G plc held 5,197,349 shares of Barinthus Biotherapeutics worth $5.2M as of Q2 2026.
M&G plc left its Barinthus Biotherapeutics share count unchanged in Q2 2026.
Barinthus Biotherapeutics made up 0.03% of M&G plc's portfolio in Q2 2026, its #255 holding.
M&G plc first reported a position in Barinthus Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
M&G plc's Barinthus Biotherapeutics position peaked at $10.4M in Q1 2024.
3 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on M&G plc's 13F filing for Q2 2026, filed 6 Aug 2026.